Other relevant Information

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the communications are available in the Web page of the CNMV.

2024

Grifols completes the closing of the private placement. All closing conditions of the RCF Extension have been fulfilled December 23, 2024
Grifols reports the closing of private placement of Senior Secured Notes and Revolving Credit Facility extension December 11, 2024
Grifols' Board of Directors unanimously appoints Pascal Ravery and Paul S. Herendeen as new members of the Board December 9, 2024
Thomas Glanzmann becomes non-executive Chairman September 23, 2024
Resolutions adopted by the Board of Directors regarding the announcement of a possible transaction to be carried out jointly by the family shareholders and Brookfield July 19, 2024
Grifols announces changes in the company's Board of Directors July 16, 2024
Resolutions adopted by the Board of Directors regarding the announcement of a possible transaction to be carried out jointly by the family shareholders and Brookfield July 12, 2024
Grifols names Mr. Rahul Srinivasan new CFO from next September July 4, 2024
Grifols reports that the proceeds received from the sale of a stake in SRAAS have been deposited into its bank account in Spain. July 3, 2024
Grifols provides explanations on credit rating agencies updates and the news published in media June 27, 2024
Grifols completes sale of a 20% equity stake in Shanghai RAAS and forges strategic alliance with Haier Group June 18, 2024
Information on the resolutions approved at the General Shareholders' Meeting of June 14, 2024 June 14, 2024
Grifols reports the closing of the private placement of additional EUR 300 million senior secured notes June 04, 2024
Grifols changes the category of Board Members Raimon Grifols Roura and Víctor Grifols Deu May 31, 2024
Call notice of the Ordinary General Shareholders' Meeting of Grifols, S.A. 2024 May 10, 2024
Grifols announces several agreements approved by the Board of Directors to strength it’s corporate governance system May 07, 2024
Grifols on track to close its strategic alliance with Haier in first half 2024 May 06, 2024
Grifols successfully completes its EUR 1 billion private placement of senior secured notes April 30, 2024
Grifols announces signing of private offering of EUR 1 billion senior secured notes due 2030 April 23, 2024
Grifols names new Secretary (non member) of the Audit Committee April 18, 2024
Grifols announces the commencement of the refinancing process April 10, 2024
Clarification to the CNMV requirements 04.04.24 April 4, 2024
Grifols provides responses to CNMV March 21 report April 4, 2024
Nacho Abia begins tenure as new Grifols CEO April 2, 2024
Grifols continues to execute its deleveraging path March 14, 2024
Grifols reports its 2023 Consolidated Annual Accounts March 8, 2024
Grifols additional information March 1, 2024
Grifols provides further information on the Free Cash Flow expected for 2024 and onwards March 1, 2024
Grifols announces the completion of the confirmatory due diligence by Haier on SRAAS transaction March 1, 2024
Grifols appoints new Board member February 27, 2024
Grifols comments on the false insinuations published by a short-seller February 20, 2024
Grifols changes the category of Board Member Albert Grifols Coma-Cros February 6, 2024
Grifols changes its corporate governance structure February 5, 2024
Grifols filed a lawsuit against Daniel Yu, Gotham City Research LLC, General Industrial Partners LLP, Cyrus de Weck, and their affiliates. January 26, 2024
Haier Group reaffirms its Commitment to acquiring 20 % of Shanghai RAAS January 14, 2024
Grifols invites investors to listen to conference call on January 11 January 10, 2024
Information as a continuation of the communications filed yesterday by the Company as a consequence of the Gotham City Research report January 10, 2024
Grifols extends their comments on the false information published by Gotham January 9, 2024
Grifols comments on the false information published by Gotham January 9, 2024

2023

Changes to the composition of Grifols Board of Directors December 19, 2023
Amendment of the Internal Regulations of the Board of Directors December 19, 2023
The Board of Directors approves the clawback policy October 20, 2023
Information on the resolutions approved at the General Meeting of Shareholders on June 16, 2023 June 16, 2023
Call notice of the General Shareholders' Meeting of Grifols, S.A. 2023 May 12, 2023
Grifols approves a long term incentive plan based May 10, 2023
Grifols realigns management structure to simplify its corporate governance May 8, 2023
Reorganization of the Audit Committee April 18, 2023
Amendment of the Internal Regulations of the Board of Directors February 24, 2023
Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation February 21, 2023
Grifols announces comprehensive operational improvement plan including EUR 400 million annualized cost savings initiative February 15, 2023

2022

Grifols' statement on articles published in certain Spanish media October 21, 2022
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson October 3, 2022
Board of Directors communication in the context of considerable geopolitical uncertainty and market volatility September 26, 2022
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada September 7, 2022
Grifols sold MedKeeper to affiliates of the US company Becton Dickinson for US$ 93 million July 28, 2022
Information on the resolutions approved at the General Meeting of Shareholders on June 10, 2022 June 10, 2022
Call notice of the General Shareholders' Meeting of Grifols, S.A. 2022 May 6, 2022
Grifols restates the consolidated annual accounts of the fiscal year 2021 April 28, 2022
Grifols completes the acquisition of Biotest April 25, 2022
Grifols obtains all regulatory approvals to close the Biotest acquisition April 12, 2022
Audit Committee and Sustainability Committee reorganization, as well as the appointment of the new Lead Independent Director of Board of Directors February 28, 2022

2021

Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion November 17, 2021
Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest October 5, 2021
Grifols initiate the launch of a €2bn equivalent senior unsecured notes September 27, 2021
Consent solicitation results on the lenders under Credit Agreement and the European Investment Bank to amend certain provisions of the senior debt August 16, 2021
Consent solicitation results on Secured and Unsecured Notes to amend certain provisions of the senior debt August 6, 2021
Commencing a consent solicitation to amend certain provisions of the senior debt July 30, 2021
Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan July 30, 2021
Grifols announces a strategic investment from GIC of USD 1 billion June 30, 2021
Termination of the buyback programme June 14, 2021
Recurring information under the buy-back programme of shares June 11, 2021
Recurring information under the buy-back programme of shares May 31, 2021
Information on the specific dividend payment conditions May 31, 2021
Recurring information under the buy-back programme of shares May 25, 2021
Information on the resolutions approved at the General Meeting of Shareholders on May 21, 2021 May 21, 2021
Recurring information under the buy-back programme of shares May 17, 2021
Recurring information under the buy-back programme of shares May 10, 2021
Recurring information under the buy-back programme of shares May 3, 2021
Recurring information under the buy-back programme of shares April 26, 2021
Recurring information under the buy-back programme of shares April 19, 2021
Notice of Annual General Shareholders' Meeting 2021 April 16, 2021
Recurring information under the buy-back programme of shares April 12, 2021
Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S. April 7, 2021
Recurring information under the buy-back programme of shares April 6, 2021
Recurring information under the buy-back programme of shares March 29, 2021
Recurring information under the buy-back programme of shares March 22, 2021
Buy-back plan of shares March 12, 2021
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen March 9, 2021
Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation March 1, 2021
The Regulations of the Sustainability Committee February 22, 2021
Grifols begins a new COVID-19 trial containing anti-SARS-CoV-2 polyclonal antibodies January 19, 2021

2020
Grifols amends certain articles of the Regulations of the Board of Directors and creates a Sustainability Committee December 16, 2020
Grifols closes the acquisition of Alkahest December 15, 2020
Grifols strategically expands its operations into Egypt November 24, 2020
Grifols acquires the remaining 49% of MedKeeper November 9, 2020
Information on the resolutions approved at the General Meeting of Shareholders on October 9, 2020 October 9, 2020
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S. October 1, 2020
Grifols continues strengthening its innovation strategy with the acquisition of Alkahest September 7, 2020
Notice of Annual General Shareholders' Meeting 2020 September 4, 2020
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million July 20, 2020
Grifols reinforces its liquidity position to EUR 1,700 million May 7, 2020
Grifols and the Public Investment Fund of Saudi Arabia to boost plasma medicines self-supply in the region February 18, 2020